Mutua de Terrassa -ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2023

  1. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

2020

  1. Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: A multidisciplinary opinion document

    Revista Espanola de Quimioterapia, Vol. 33, Núm. 1, pp. 49-67

2018

  1. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients

    Clinical Microbiology and Infection, Vol. 24, Núm. 5, pp. 546.e1-546.e8

2012

  1. Pneumonia treated in the internal medicine department: Focus on healthcare-associated pneumonia

    Clinical Microbiology and Infection, Vol. 18, Núm. 8, pp. 786-794

2009

  1. Management of methicillin-resistant Staphylococcus aureus infections

    Clinical Microbiology and Infection, Vol. 15, Núm. 2, pp. 125-136

2008

  1. Staphylococcus spp. en España: Situación actual y evolución de la resistencia a antimicrobianos (1986-2006)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 5, pp. 269-277

2007

  1. Impact of amoxicillin, associated or not with clavulanic acid, on pharyngeal colonization and selection of Streptococcus pneumoniae resistance in children under 5 years of age

    European Journal of Pediatrics, Vol. 166, Núm. 5, pp. 467-471

2006

  1. Alterations of the penicillin-binding proteins and murM alleles of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 57, Núm. 2, pp. 224-229

  2. Combinations of PBPs and MurM protein variants in early and contemporary high-level penicillin-resistant Streptococcus pneumoniae isolates in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 57, Núm. 5, pp. 983-986

2005

  1. New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 6, pp. 2237-2245

2004

  1. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae Clones, Spain

    Emerging Infectious Diseases, Vol. 10, Núm. 10, pp. 1751-1759

  2. Spectrum of antibiotic resistance of the Spain14-5 Streptococcus pneumoniae clone over a 22 year period

    Journal of Antimicrobial Chemotherapy, Vol. 53, Núm. 4, pp. 620-625

2003

  1. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836

  2. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 6, pp. 967-973

  3. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones

    International Journal of Antimicrobial Agents

2002

  1. Meningitis neumocócica en niños Españoles: Incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico

    Anales Espanoles de Pediatria, Vol. 57, Núm. 4, pp. 295-300

1999

  1. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with β-lactam monotherapy

    Journal of Chemotherapy, Vol. 11, Núm. 4, pp. 266-272